HER2 mutation is important for clinical treatment and prognosis evaluation in cancer patients and has been found to be a predictive marker to HER2-targeted therapy in breast and gastric cancer (Calhoun and Collins, 2015; Jiang et al., 2018). This evidence concerns the gene ERBB2 and cancer.